Bleomycin, etoposide, and cisplatin (BEP) regimen for testicular cancer

Hospital Pharmacy

Volumn 38, Issue 7, 2003, Pages 638-644

  Roark, Kathleen M ^c   Waddell, J Aubrey ^b   Solimando Jr , Dominic A ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; DIURETIC AGENT; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; ETOPOSIDE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; METOCLOPRAMIDE; ONDANSETRON; PARACETAMOL; PROCHLORPERAZINE; SEROTONIN ANTAGONIST; SODIUM CHLORIDE; THIETHYLPERAZINE;

ACUTE KIDNEY TUBULE NECROSIS; AZOOSPERMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DOSE KIDNEY FUNCTION RELATION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INFUSION; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG FIBROSIS; LUNG TOXICITY; LYMPHOMA; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OLIGOSPERMIA; OTOTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRACTICE GUIDELINE; RAYNAUD PHENOMENON; REPRODUCTIVE TOXICITY; REVIEW; SKIN TOXICITY; TESTIS CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0038001037     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870303800702     Document Type: Review

References (28)

1. National Comprehensive Cancer Network. NCCN testicular cancer practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Rockledge, PA: National Comprehensive Cancer Network; 2003.
2. Shelley MD, Burgon K, Mason MD. Treatment of testicular germ-cell cancer: A Cochrane evidence-based systematic review. Cancer Treat Rev. 2002;28:237-53.
3. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435-40.
4. de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular nonseminoma; a randomised study of the EORTC genitourinary tract cancer cooperative group. Br J Cancer. 1995;71:1311-4.
5. Bokemeyer C, Kohrmann O, Tischler J, et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with good-risk metastatic nonseminomatous germ cell tumors. Ann Oncol. 1996;7:1015-21.
6. de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15:1837-43.
7. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19:1629-40.
8. Toner GC, Stockler MR, Boyer MJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: A randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet. 2001;357:739-45.
9. de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP vs four cycles of VIP in patients with intermedicate-prognosis metastatic testicular nonseminoma: A randomized study of the EORTC genitourinary tract cancer cooperative group. Br J Cancer. 1998;73:828-32.
10. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-9.
11. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm. 1999;56:729-64.
12. National Comprehensive Cancer Network. NCCN antiemesis practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Rockledge, PA: National Comprehensive Cancer Network; 2003.
13. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-94.
14. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993;50:147-158.
15. Kintzel PE. Anticancer drug-induced kidney disorders: Incidence, prevention and management. Drug Safety. 2001;24:19-38.
16. Weiss RB. Hypersensitivity reactions. Semin Oncol. 1992;19:458-77.
17. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol. 2000;18:3558-85.
18. Lyman GH, Balducci L. A cost analysis of hematopoietic colony-stimulating factors. Oncology. 1995;9(suppl 11):85-91.
19. Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer. 1998;34:1857-64.
20. Lyman GH, Balducci L. Update of the economic analyses of the use of colony-stimulating factors. Curr Opin Hematol. 1999;6:145-151.
21. Lyman GH. A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care. Eur J Cancer. 2000;36(suppl 11):S15-S21.
22. Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer. 1982;49:1796-9.
23. Larson DL. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg. 1985;75:397-402.
24. Mullin S, Beckwith MC, Tyler LS. Prevention and management of antineoplastic extravasation injury. Hosp Pharm. 2000;35:57-74.
25. Stephenson WT, Poirier SM, Rubin L, et al. Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J Clin Oncol. 1995;13:2278-80.
26. Patterson WP, Reams GP. Renal and electrolyte abnormalities due to chemotherapy. In: Perry MC, ed. The Chemotherapy Sourcebook. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 494-504.
27. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21:33-64.
28. King PD, Perry MC. Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am. 1995;24:969-89.